Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19  Drug: sarilumab, drug: placebo  United States/COVID‐19  400, all, 18 years and older  Treatment  Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: